Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma ...

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma ...

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma ...

Toilet Cover May Significantly Reduce Aerosol Exposure in Hospital Bathrooms ...

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma ...

Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose ...